Effect of lansoprazole on the epigastric symptoms of functional dyspepsia (ELF study): A multicentre, prospective, randomized, double-blind, placebo-controlled clinical trial.
Abstract
BACKGROUND: Since the publication of the Rome III criteria for functional dyspepsia (FD), the evidence about the efficacy of half-dose of proton pump inhibitors for dyspepsia symptoms have been limited. OBJECTIVE: To examine the efficacy of lansoprazole for functional dyspepsia (FD) diagnosed with the Rome III criteria by the multicentre, double-blind, randomized, placebo-controlled study in Japan. METHODS: A total of 54 FD participants were randomized to lansoprazole 15 mg once daily or placebo for a 4-week double-blind treatment period. The primary efficacy endpoint was an overall dyspeptic symptom relief rate evaluated by 5-point Likert scale scores. The alteration of dyspeptic symptom scores during the study period was also assessed. RESULTS: At week 4, the overall dyspeptic symptom relief rates were higher in the lansoprazole group (30.4%) than in the placebo group (6.7%) (p = 0.045). The scores for epigastric pain (p = 0.045) and epigastric burning (p = 0.03) were significantly improved in the lansoprazole group compared to the placebo group, whereas the improvement of the scores for postprandial fullness (p = 0.81) and early satiation (p = 0.33) was not different between lansoprazole and placebo groups. CONCLUSIONS: Lansoprazole 15 mg ameliorates dyspeptic symptoms, particularly the epigastric pain syndrome-related symptoms of FD.
AI evidence extraction
Main findings
At week 4, overall dyspeptic symptom relief was higher with lansoprazole 15 mg once daily (30.4%) than placebo (6.7%) (p=0.045). Epigastric pain (p=0.045) and epigastric burning (p=0.03) improved significantly versus placebo, while postprandial fullness (p=0.81) and early satiation (p=0.33) did not differ between groups.
Outcomes measured
- Overall dyspeptic symptom relief rate (5-point Likert scale)
- Epigastric pain score
- Epigastric burning score
- Postprandial fullness score
- Early satiation score
Limitations
- Small sample size (n=54)
- Short treatment duration (4 weeks)
View raw extracted JSON
{
"study_type": "randomized_trial",
"exposure": {
"band": null,
"source": null,
"frequency_mhz": null,
"sar_wkg": null,
"duration": "4-week double-blind treatment period"
},
"population": "Participants with functional dyspepsia (FD) diagnosed with the Rome III criteria in Japan",
"sample_size": 54,
"outcomes": [
"Overall dyspeptic symptom relief rate (5-point Likert scale)",
"Epigastric pain score",
"Epigastric burning score",
"Postprandial fullness score",
"Early satiation score"
],
"main_findings": "At week 4, overall dyspeptic symptom relief was higher with lansoprazole 15 mg once daily (30.4%) than placebo (6.7%) (p=0.045). Epigastric pain (p=0.045) and epigastric burning (p=0.03) improved significantly versus placebo, while postprandial fullness (p=0.81) and early satiation (p=0.33) did not differ between groups.",
"effect_direction": "benefit",
"limitations": [
"Small sample size (n=54)",
"Short treatment duration (4 weeks)"
],
"evidence_strength": "moderate",
"confidence": 0.74,
"peer_reviewed_likely": "yes",
"keywords": [
"functional dyspepsia",
"Rome III criteria",
"lansoprazole",
"proton pump inhibitor",
"randomized",
"double-blind",
"placebo-controlled",
"epigastric pain syndrome"
],
"suggested_hubs": []
}AI can be wrong. Always verify against the paper.
Comments
Log in to comment.
No comments yet.
NNEMF synthesis
Synthesis pending.